Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexis Talbot

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Kidney International|February 15, 2026
B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B cell Depletion for Treatment of Refractory HLA SensitizationJuliette Leon, Olivier Aubert, Magali Devriese, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
Nature Biotechnology|August 25, 2022
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktailsBrian R Shy, Vivasvan S Vykunta, Alvin Ha, et al.
Blood|November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorAnaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.
Kidney International|December 29, 2022
Pathological characteristics of light chain crystalline podocytopathySamih H Nasr, Satoru Kudose, Vincent Javaugue, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Blood|November 21, 2024
Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohortPierre-Edouard Debureaux, Stéphanie Poulain, Stéphanie Harel, et al.
Blood Advances|February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jérôme Lambert, et al.
Nature Communications|July 15, 2022
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistanceIan D Ferguson, Bonell Patiño-Escobar, Sami T Tuomivaara, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Kidney International|February 15, 2026
B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B cell Depletion for Treatment of Refractory HLA SensitizationJuliette Leon, Olivier Aubert, Magali Devriese, et al.
Leukemia|September 15, 2025
Molecular profiling and risk stratification in solitary bone plasmacytomaBarbara Burroni, Stéphanie Harel, Raphaele Seror, et al.
British Journal of Haematology|November 18, 2025
NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myelomaGaurav Agarwal, Mohammad Kazeroun, Mirian Salazar, et al.
Nature Biotechnology|August 25, 2022
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktailsBrian R Shy, Vivasvan S Vykunta, Alvin Ha, et al.
Blood|November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorAnaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.
Kidney International|December 29, 2022
Pathological characteristics of light chain crystalline podocytopathySamih H Nasr, Satoru Kudose, Vincent Javaugue, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Blood|November 21, 2024
Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohortPierre-Edouard Debureaux, Stéphanie Poulain, Stéphanie Harel, et al.
Blood Advances|February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jérôme Lambert, et al.
Nature Communications|July 15, 2022
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistanceIan D Ferguson, Bonell Patiño-Escobar, Sami T Tuomivaara, et al.
Pageof 7